Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:10:41.209Z.
Consensus retrieved: 2026-10-06T08:42:06.871Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:10:41.209Z.
Quote observation: 2026-10-06T15:10:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3a5f53e60080e4c0bd8028294acadec9828b96594dd07725d589d3e2217ece04
Forward PE Ratio (N/A) = Dated Quote Price ($1.47) / Consensus Forward EPS ($-0.60)
FORWARD PE RATIO
N/A
Allogene Therapeutics, Inc.
Market Cap
$505.65M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | $505.65M | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $515.76M | N/A |
| Oculis Holding AG (OCS)vs › | $495.38M | N/A |
| 908 Devices Inc. (MASS)vs › | $517.35M | N/A |
| Evolus, Inc. (EOLS)vs › | $488.92M | N/A |
| Altimmune, Inc. (ALT)vs › | $523.14M | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $485.03M | 25.08 |
| Bright Minds Biosciences Inc. (DRUG)vs › | $478.35M | N/A |
| Arvinas, Inc. (ARVN)vs › | $477.46M | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $534.31M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.47, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.60 | $-0.64 – $-0.55 | 8 | n/m |
| 2027-12-31 | $-0.64 | $-0.69 – $-0.56 | 6 | n/m |
| 2028-12-31 | $-0.55 | $-0.82 – $-0.20 | 10 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
